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Abstract
Background: Smoking cessation services provide support to smokers who desire to quit. Published studies to date
have looked at the cost and benefit of service provision but typically focus on clinical trial data. Using routinely
collected observational data, this study examined the costs involved in providing a service in terms of average
health care expenditure per successful quit attempt in addition to population – level cost-effectiveness measures.
Methods: Data were analysed from Quit-51 smoking cessation service across five English regions between March
2013 and March 2016 (n = 9116). For each user, costs were estimated in relation to: (i) time spent with advisers; (ii)
prescription of pharmacotherapy. The total costs compared against self-reported quit at 12 weeks, which represents
the time period for which the service is offered. Cost per quit (CPQ), with 95% confidence interval (CI), was
calculated by relating total expenditure to the number of quitters, firstly for the whole dataset and then by
subgroups of key categorical variables, namely; gender, age group, the Fagerstrom test for nicotine dependence
(FTND) and Index of Multiple Deprivation (IMD). Confidence intervals (CIs) for the mean estimates were derived
using a non-parametric bootstrap procedure. Parameters derived from the calculation in relation to treatment were
used to estimate potential long-term population outcomes under a scenario where the Quit 51 prescription was
rolled out nationally.
Results: The overall mean CPQ for this sample as estimated at 12 weeks was £403.51 (95% CI = £393.36 to £413.76).
The estimated CPQs at this time point were comparable for those aged 12–19 (£423.56, 95% CI = £369.45 to
£492.60) and those aged 20–29 (£430.76, 95% CI = £395.95 to £470.56). Differences were also seen in relation to
other subgroups considered. The treatment parameters translated to a projected increase of 1.5 quality-adjusted life
years (QALYs) per 1000 smokers in the short-term and 23.4 QALYS per 1000 smokers based on a lifetime horizon.
Conclusions: These figures throw light on service expenditure for each successful quit over the timeframe for
which the service is offered in addition to highlighting variability in these costs across different subgroups of the
user population.
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Background
Smoking is a major cause of preventable death and poor
health in countries across the world [1]. In particular,
smoking is linked to lung and other cancers [2] as well
as heart disease, stroke and a range of pulmonary condi-
tions. Bans on smoking in public places, coupled with
increasing awareness of the adverse effects on health
have helped to reduce the number of smokers in many
countries [3]. As well as being beneficial to public
health, reducing the prevalence of smoking relieves pres-
sure on health services as a result of the consequent
drop in smoking related admissions and achieving
further reduction remains a priority for healthcare
providers around the world [4].
In the United Kingdom, support is offered to those
wishing to quit through the provision of smoking cessa-
tion services which operate according to guidelines laid
out by the National Centre for Smoking Cessation Treat-
ment (NCSCT) based on the latest available evidence on
effective cessation strategies [5, 6]. Similar services exist
in other countries [7]. Smoking services provide access
to advice over a number of sessions with a qualified
adviser and tailored pharmacotherapy in the form of
Nicotine Replacement Therapy, or NRT [8], which is
offered for this purpose. Varenicline (proprietary name
in UK - Champix) and bupropion (proprietary name in
UK - Zyban) are also available, although the last of these
is rarely used in light of concerns over side-effects [9].
Of these three treatments, varenicline consistently
demonstrates superiority with respect to quit rate based
on results from clinical trials [10, 11], although alterna-
tive treatments not currently available in the UK, e.g.
cytisine, may be more effective still [12]. It is less clear
whether bupropion is superior to NRT or vice versa,
although it is well established that both perform well in
relation to placebo [13]. Whilst these findings appear to
hold over a number of studies, the projected quit rates
and cost effectiveness have not been fully characterised
and the decision to prescribe a particular treatment over
alternatives may be based on the preference of clinical
staff rather than an analysis of client characteristics.
In a climate where healthcare expenditure is increasing
in line with new technologies and greater demand, such
decisions should be informed by consideration of costs
and benefits [14]. Economic models of these smoking
cessation interventions from a number of studies indi-
cate that varenicline is the most cost-effective according
to various measures such as Quality Adjusted Life Years
(QALYs), cost savings and reduction in incidences of
smoking-related mortality [15–17]. Results with respect
to pharmacotherapy are highly variable when compared
across different studies and countries [18]. The costs
and benefits used in models of the cost effectiveness of
smoking cessation interventions are typically derived
from clinical randomised controlled trials (RCT). It is
well recognised that the cost-effectiveness of a given
intervention can be different in a real-world as opposed
to a research context [19–21].
Our primary aim was to calculate the cost per quit
(CPQ) in relation to the above treatments using data
collected by a smoking cessation service, which affords
an insight into the costs in routine clinical practice. We
also carried out CPQ calculations across key subgroups
in the population of smoking cessation service users. As
a secondary aim, figures arising from these calculations, in
relation to the three pharmaceutical treatments, were uti-
lised in order to calculate what the long-term population-
level benefits may be if the Quit 51 programme were
rolled out nationally using a freely available tool designed
for the calculation of long-term population health param-
eters, the EQUIPT calculator [22].
Methods
Smoking cessation services
Quit 51 offer a smoking cessation service in accordance
with National Institute for Health and Care Excellence
(NICE) guidelines [6]. The remit of the service is to pro-
vide a maximum of 12 sessions of support with an accre-
dited adviser and provision of tailored pharmacotherapy
to smokers attempting to quit. A session is typically of
15 min duration although the introductory session will
generally take longer in order to cover triaging and
discussions around individual background and require-
ments. Assuming a patient continues with the service
for the full duration, they should receive a minimum of
90 min’ contact time with an adviser covering a period
up to 12 weeks after quitting.
Data
Data were provided by Quit 51 on patients across six
Clinical Commissioning Groups (CCGs) in England for
whom the requisite information on treatment and
contact time was available. The period covered varied
between the different CCGs, but all records fell within
the dates 15 March 2013 to 16 March 2016 inclusive
(using quit date as the criterion). Best practice was
observed in terms of data handling and the project
conformed with the principles laid out in the World
Medical Association Declaration of Helsinki [23].
At the outset, there were 15,682 records, but a number
of restrictions were applied before calculations were
made. Observations were removed where: (i) quit date
was before subsequent to 9 December 2015, N = 1950
(ii) smoker recorded as pregnant, N = 802 (iii) either no
or multiple pharmacotherapy was recorded, N = 4254.
The first of steps was taken to ensure as far as possible
that all records were complete at the date of data com-
pilation (March 13 2016). Pregnant users of Quit 51
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were not considered here as this subgroup is offered a
specialist service which differs in key respects from the
standard service. Instances where no or multiple treat-
ment were omitted due to a possibility of misrecording.
The above restrictions gave rise to a dataset of 9116 ob-
servations derived from 7783 individuals. In order to
gain a global perspective on CPQ over this period, repeat
observations on individual clients were retained in the
calculation. Of the original six clinical regions consid-
ered (East Sussex, Sandwell, Surrey, Telford and Wrekin,
Walsall, Worcester) only five were used in this calcula-
tion as all the Surrey records fell after the exclusion date
of 9 December 2015.
Individual costs
A cost for each individual using the service was
estimated based on: (i) pharmacotherapy prescribed; (ii)
time spent with an adviser.
With respect to pharmacotherapy, the costs, including
prescription and value added tax (VAT) for each treat-
ment were as follows: NRT (combination) - £19.95 per
week; Varenicline - £76.80 per month/£38.40 per 2 weeks;
and Bupropion - £69.45 per month/£34.73 per 2 weeks.
For clients using NRT, treatment was made available for
use to coincide with the agreed quit date. Varenicline, on
the other hand, was prescribed between 8 and 14 days
prior to the quit date in order to allow for the medical
properties of this treatment to take effect. Sometimes an
anomaly was observed whereby prescription of these
treatments occurred after the 12-week treatment period.
Since our inference was based on cessation at 12 weeks,
prescription costs were only considered within this time-
frame. Table 1 describes how doses were prescribed over
time according to treatment pathway. The derivation of
medication costs was assessed according to the number of
doses prescribed and the individual dose quantities (costs
for dose quantities provided above). If, as in some
instances, the number of doses indicated in the dataset
was above the maximum specified in Table 1, for the
purposes of the calculation this was fixed at this max-
imum, so as not to include costs beyond the standard
treatment timeframe.
The time spent with an adviser was recorded for each
session attended. The figures around adviser time for
each session were based on average values, although it is
conceivable that a degree of variability exists on a case-
by-case basis, for example, in relation to distance trav-
elled by an adviser. The total time spent with an adviser
was taken from a variable called “Total Contact Time”
in the master database, covering the full 12 weeks of
potential engagement with the service. The estimated
time was multiplied by an hourly charge of £26.32, based
on the following breakdown of costs: (i) Adviser - £23.65
per hr.; (ii) Room - £0.20 per hr.; (iii) Equipment - £0.49
per hr.; (iv) Travel - £0.74 per hr.; and (v) Advertising -
£1.24 per hr. This itemisation of costs in relation to both
pharmacotherapy and counselling was given by the
service provider, based on the financial year 2015–2016.
Central overhead costs for the service were not
included.
Cost-per-quit calculation and confidence intervals
Using the above method, we derived individual costs up
to the full potential 12 weeks’ of service use. As an
outcome we used 12-week self-reported quit. This was
recorded as a binary response (0 or 1) where 0 indicated
‘failed quit attempt’ and 1 indicated ‘successful quit at-
tempt’. The average CPQ for this dataset was calculated
at this time point as follows:
CPQ ¼ T
nquit
where CPQ = the average CPQ in the sample, T = the
total costs summed across all patients and nquit = the
total number of successful quits (i.e. where binary out-
come of quit success = 1). The average CPQ was then
also calculated for all categories of the following factors:
(i) Age, (ii) Gender, (iii) Treatment, (iv) Fagerstrom test
for nicotine dependence (FTND) index [24] and the
Index of Multiple Deprivation (IMD) [25]. Age was split
into arbitrary categories (< 19, 20–29, 30–49, 50–69 and
70+ years) for this purpose.
The FTND index is a score (1–10) reflecting an
individual’s degree of dependence on cigarettes, based
on a number of questions. The lower the score, the
lower the dependence inferred. To simplify presentation,
this was re-categorised into four groups (0–3, 4–5, 6–7
and 8–10) prior to analysis such that each category
consisted of a suitable number of records for statistical
purposes. The IMD is an area deprivation score mapped
to postcode and scored on a scale of 1–10 inclusive, with
lower scores indicating greater deprivation. In order to
Table 1 Chronological pattern of medication dose (in weeks)
for users of Quit 51 smoking cessation service according to
pharmacotherapy prescribed and the prescription route
(through pharmacy or other)
Treatment
(prescription pathway)
Chronological pattern of dosing
covering 12 weeks of service
use (dose quantity in weeks)
Max. no.
of doses
NRT (all) 1 + 1 + 1 + 1 + 1 + 1 +
1 + 1 + 1 + 1 + 1 + 1
12
Varenicline (pharmacy) 2 + 2 + 2 + 2 + 2 + 2 6
Varenicline (any route
other than pharmacy)
2 + 2 + 4 + 4 4
Bupropion (all) 2 + 2 + 4 3
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facilitate interpretation when referring to a deprivation
effect, these scores were inverted so that 1 = least
deprived/most affluent area with increasing score indi-
cating a greater degree of deprivation (maximum = 10).
As with FTND, this measure was grouped into suitably
large categories prior to the calculation (deprivation = 1–
3, 4–6, 7–8 and 9–10 respectively).
Derivation of confidence intervals was complicated by
the fact that the distribution of costs was non-standard,
in addition to the fact that there were two populations
to take into account - successful quits and failed quits.
Thus there were different sources of uncertainty to
contend with: (i) the costs within both the failed and
successful quit subgroups; and (ii) the proportion of
successful/failed quits.
To avoid assumptions about the underlying distribu-
tions a bootstrap procedure was used to simultaneously
deal with both sources of uncertainty. For a given simu-
lation, the original population was sampled with replace-
ment N times where N = the number of observations in
the population. If a given record was sampled, both the
cost and quit status were retained. From this bootstrap
sample, a CPQ was calculated as above (dividing the
total cost by the number of successful quits). This pro-
cedure was repeated 1000 times giving a bootstrap sam-
ple from which a 95% confidence interval was derived
with reference to the percentiles at 2.5% and 97.5%. This
procedure was carried out within each subgroup with
the value N being determined by the relevant subgroup
sample size.
All the CPQ calculations were carried out in GenStat
[26] 18th edition.
In order to extrapolate the short-, medium- and long-
term healthcare costs and outcomes (QALYs) of Quit 51,
a recently developed return on investment (ROI) model,
known as EQUIPTMOD [22], was applied using the
treatment parameters used here. The EQUIPTMOD is a
European initiative to quantify the utility on investment
in protection from tobacco [27] and allows users to
simulate the costs and QALYs of smoking cessation in-
terventions under various user-defined scenarios. Details
regarding the EQUIPT model and underlying assump-
tions are described elsewhere [22] and the software is
available at the following website (http://equipt.eu).
Extrapolating from the five regions represented in our
calculation, a scenario was assumed in which Quit 51
was rolled out to the whole of England. This was then
compared against a baseline scenario in which no smok-
ing cessation support was available. The baseline thus
represented theoretical gross cost of tobacco smoking in
the absence of interventions. The difference in costs
(both treatment costs due to smoking attributable dis-
eases and costs of implementing Quit 51 at the national
level) and QALYs could then be regarded as the benefit
derived from the Quit 51 service. In order to achieve
this, the EQUIPTMOD was first run according to a
“baseline” setting of no treatment. Then, we added pa-
rameters based on the ‘Quit 51 approach’ to the model
via three specific interventions that characterise the Quit
51 service (and Stop Smoking Services more generally),
i.e. NRT + support; varenicline + support; and bupropion
+ support, using the ‘customise interventions’ functional-
ity of EQUIPTMOD. Three parameters were entered for
each treatment arm to model the Quit 51 approach in
EQUIPTMOD, namely the uptake rate amongst quitters,
the cost per user of the service (regardless of whether
the individual has quit or not) and projected relative rate
of abstinence (relative to no treatment baseline of 4%) at
12 months. The values entered for uptake and cost per
head reflected those in our sample, whereas the relapse
rates were based on 12-month estimates as used in
EQUIPTMOD for users of NRT, varenicline and bupro-
pion (albeit without behavioural support as is provided
in the Quit 51 prescription).
Results
Summary statistics in Table 2 highlight trends in quit
rates between different subgroups before we consider re-
sults from statistical analysis. Frequency of prescriptions
shows that NRT was prescribed for more than 80% of
the clients in this sample and also highlights the rarity
with which bupropion was prescribed (0.4% of clients).
The overall average CPQ was £403.59 (95% CI =
£393.36 to £413.76) at 12 weeks (Table 3). Differences
were observed between age groups such that CPQ
tended to decrease with increasing age, although for the
two youngest age groups (12–19 and 20–29 years) the
average costs were effectively indistinguishable when the
CIs are taken into account (mean CPQs; £423.56 and
£430.76 respectively) as was the case also for the two
oldest age groups (mean CPQ = £393.22 and £390.88 for
the 50–69 and 70+ year age groups respectively).
Regarding the pharmacotherapy treatment groups,
varenicline use was associated with a slightly higher
CPQ than NRT use (mean CPQ = £401.60 and £413.06
for varenicline and NRT respectively), but overlapping
confidence intervals for these estimates implied insuffi-
cient evidence to conclude that this represented a
significant difference. The cost per quitter for smokers
prescribed bupropion was markedly lower than for the
other two treatments (mean CPQ and 95% CI; £226.56,
£177.21 to £314.21).
Our calculations showed an elevated average cost for
females relative to males (mean CPQ = £412.67 and
£393.97 respectively) with the confidence intervals indi-
cating that this difference was statistically significant.
The costs steadily increased in line with increased
tobacco dependence (mean CPQ = £378.87, £411.78,
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Table 2 Summary statistics for key variables in the sample based on quit rate at 12 weeks (N = 9116)
N (%) N quit at 12 weeks (%)
Age (mean = 44.8 yrs) 12–19 yrs 509 (5.6%) 116 (22.8%)
20–29 yrs 1189 (13.1%) 296 (24.9%)
30–49 yrs 3911 (43.0%) 1262 (32.3%)
50–69 yrs 2955 (32.5%) 1068 (36.1%)
70+ yrs 538 (5.9%) 192 (35.7%)
Gender Male 4249 (46.6%) 1425 (33.5%)
Female 4867 (53.4%) 1510 (31.0%)
Treatment NRT 7373 (80.1%) 2117 (28.7%)
varenicline 1708 (18.7%) 799 (46.8%)
bupropion 35 (0.4%) 19 (54.3%)
FTND (Mean = 4.89) 0–3 1534 (26.2%) 622 (40.5%)
4–5 1884 (32.2%) 727 (38.6%)
6–7 1676 (28.6%) 641 (38.2%)
8–10 766 (13.1%) 236 (30.8%)
Deprivation (Mean = 7.22) 1–3 886 (10.8%) 319 (36.0%)
4–6 1838 (22.4%) 635 (34.5%)
7–8 2157 (26.3%) 698 (32.4%)
9–10 3321 (40.5%) 1180 (35.5%)
Table 3 Average cost per quit (with approximate 95% CI) calculated at the 12 week time point, with supporting information
Variable Levels 12 weeks
N Total cost (£) Cost per head (£) N quits Quit rate (%) Mean CPQ (95% CI) (£)
Age 12–19 509 49,133 96.53 116 22.79 423.56 (369.45, 492.60)
20–29 1189 127,504 107.24 296 24.89 430.76 (395.95, 470.56)
30–49 3911 512,284 130.99 1262 32.27 405.93 (391.53, 423.23)
50–69 2955 419,963 142.12 1068 36.14 393.22 (378.45, 409.60)
70+ 538 75,050 139.50 192 35.69 390.88 (357.16, 427.00)
Gender Male 4249 561,404 132.13 1425 33.54 393.97 (380.36, 407.97)
Female 4867 623,127 128.03 1510 31.03 412.67 (398.41, 427.01)
Treatment NRT 7373 850,191 115.31 2117 28.71 401.60 (389.91, 414.63)
varenicline 1708 330,035 193.23 799 46.78 413.06 (395.16, 433.55)
bupropion 35 4305 122.99 19 54.29 226.56 (177.12, 314.21)
FTND 0–3 1534 236,567 153.62 622 40.55 378.87 (359.35, 399.99)
4–5 1884 299,362 158.90 727 38.59 411.78 (393.08, 433.31)
6–7 1676 270,188 161.21 641 38.25 421.51 (401.06, 444.88)
8–10 766 120,191 156.91 236 30.81 509.28 (464.80, 562.87)
Deprivation 1–3 886 136,039 153.54 319 36.00 426.45 (396.92, 460.57)
4–6 1838 266,099 144.78 635 34.55 419.05 (398.11, 443.28)
7–8 2157 300,324 139.23 698 32.36 430.26 (408.13, 451.16)
9–10 3321 451,353 135.91 1180 35.53 382.50 (369.26, 397.69)
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£421.51 and £509.88 for binned categories of FTND;
1–3, 4–5, 6–7 and 8–10 respectively). The trend with
respect to IMD scores was not obviously linear. The
CPQ for the first 3 groups, in ascending order of
deprivation, were broadly similar (£426.45, £419.05
and £509.88 for deprivation score groups of 1–3, 4–6
and 7–8 respectively). In contrast, the average CPQ
for the group of highest deprivation (inverted IMD =
9–10) was £382.50, significantly lower than all others.
Table 4 reports the results from the analysis based on
the EQUIPTMOD. Parameters entered to simulate a
Quit 51 prescription were as follows; uptake rate –
80.1%, 18.7% and 0.4% (see Table 2); cost per user -
£115.45, £190.16 and £122.99 for NRT (see Table 3);
relative success rate (against baseline of 4% cessation) –
2.14, 2.24 and 1.6, for varenicline and bupropion
respectively in each case [4]. The figures are presented
to cover various time horizons – 2 years (short term);
5–10 years (medium term) and lifetime horizon (long
term). The Quit 51 approach produced an average of
35.21 quitters per 1000 smokers. This translated to
health gains of 1.5 QALYs per 1000 clients in the short
term to 23.4 QALYs per 1000 clients using a lifetime
horizon. Although the cost per QALY gain in the first
2 years of Quit 51 (£58,736) is well above the NICE
threshold of £20,000 per QALY, this intervention would
become cost-effective in the medium term and would be
highly cost-effective in the long term, compared with the
counterfactual scenario. For every £1 invested in Quit
51, over a lifetime horizon one would expect a return of
65p just in healthcare savings (i.e. savings coming from
treating fewer cases of smoking attributable diseases)
but this would increase to a more substantial £4.22 if
QALY gains are considered from a societal perspective.
Discussion
In this study we have used observational data recorded
by a smoking cessation service to gain an understanding
of the typical real world CPQs from a service or NHS
perspective. From these data, we estimate the average
cost per quitter at £403.59, with a significant degree of
variation seen across certain subgroups of the client
population. These calculations were based on applying
an average rate with respect to adviser time and a more
accurate picture may be obtained where more detailed
individual-level information exists. Furthermore, Quit 51
overhead costs were not included in addition to there
being no allowance made for costs to the individual of
service use (travel and parking costs etc.). Thus the fig-
ures presented here should be interpreted strictly in rela-
tion to costs associated with provision of medication
and behavioural support by stop smoking services.
Age-based results imply greater difficulty amongst the
young (teenagers and the 20–29 year old group in this
instance) in quitting, as has been reported elsewhere
[28]. This age group is an important one to reach and
support, given that the long term benefits of cessation
are greater at this stage of life than amongst those of an
older age [1]. Analysis elsewhere has shown CPQ figures
for different types of internet and mobile phone smoking
cessation assistance [29] are favourable in relation to
those presented here. Given widespread use of internet
technology amongst the young in general, this represents
an appealing alternative as a strategy for driving down
quit rates (and associated costs) with users of the service
in this age group.
These data show that average cost per quit amongst
males was slightly reduced relative to females, a finding
which is consistent with men being more likely to quit
in the context of smoking cessation services [28, 30],
although the magnitude of the difference was not great
when considered against the overall average costs ob-
served (difference = £18.70 at 12 weeks). If the reason
behind the different quit rates between men and women
was related to anxiety about weight gain due to quitting
smoking, the provision of a more comprehensive service
combining both smoking cessation and weight loss may
be worth considering [31].
Although varenicline users had a higher quit rate than
those using NRT, this didn’t translate to a lower CPQ,
Table 4 Short-, medium- and long-term costs and outcomes of the Quit 51 approach modelled using the EQUIPTMOD model [22]
based on 35.21 quitters per 1000 smokers
Metrics Time horizon
2 years 5 years 10 years Lifetime
Average healthcare costs (per smoker) £862 £2091 £3944 £11,608
Average total costs (per smoker)(includes cost of intervention) £957 £2186 £4039 £11,704
Average QALYs (per smoker) 1.57 4.53 6.57 14.81
QALY gains (per 1000)a 1.5 3.7 7.5 23.4
Cost/QALYa £58,736 £19,756 £7582 £402
Benefit-Cost ratioa(healthcare savings only) 0.07 0.16 0.29 0.65
Benefit-Cost ratioa (healthcare savings + QALY gains valued at £20,000/QALY) 0.29 0.73 1.44 4.22
aCompared with a baseline scenario of no intervention
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which was slightly higher for varenicline than NRT.
Models and analysis looking into ICERs and QALYs
elsewhere suggest varenicline is more cost-effective than
NRT [15, 16, 32], thus contrasting to a degree with the
findings in this analysis. The estimated CPQ for bupro-
pion was perhaps surprisingly low, although it should be
remembered that the standard course of treatment for bu-
propion users only amounts to three prescriptions to
cover 8 weeks in contrast to NRT and varenicline, which
are prescribed to cover a period of 12 weeks (see Table 1).
Even allowing for this, the CPQ for bupropion was strik-
ingly low which contrasts with results in the literature.
Nonetheless, the sample for this subgroup was very low
and thus associated figures should be considered indica-
tive only.
Greater CPQ with increased nicotine dependence is a
logical result of greater difficulty quitting with increased
dependence. No obvious trend was evident in relation to
the deprivation groups although it was notable that the
lowest CPQ was observed in relation to the most de-
prived group. It is possible to speculate that the higher
prevalence of smoking in the most deprived population
may mean that there is a higher proportion in this group
who have low levels of addiction compared to other
social groups, where those who can easily give up have
already done so and one is left with a rump of smokers
who find quitting very difficult.
In this preliminary work, we have only considered
CPQ across subgroups of individual factors without con-
sidering how they might covary together (e.g. age and
gender). Exploratory work indicated that some kind of
interaction may be present between gender and age
group, but this was not within the scope of the current
preliminary presentation. Nonetheless, this could pro-
vide the basis of future work, particularly if more de-
tailed individual costings become available.
In this analysis, the calculation of CPQ was primarily
restricted to a health service perspective. However, the
true cost of quitting smoking also involves the smoker’s
time and travel to and from service venues, and other
indirect costs such as leave from work or provision of
childcare. Therefore, the true cost to individuals and so-
ciety is likely to be greater than the figures we have pre-
sented here.
Our analysis was based on routinely collected service
data. It was necessary to exclude a proportion of the
data before the calculation was carried out. In the case
of exclusion on the basis of (i) date and (ii) quitter
recorded as pregnant this was a practical necessity. In
addition, some records were omitted as either no or
multiple treatment was recorded (4254 of the original
15,682 records fell into this category). This raises the
issue of data quality when dealing with data of this na-
ture and potential bias introduced due to excluded and
missing records. Furthermore, we have assumed the five
CCGs considered are approximately representative of
England as a whole. It is difficult to quantify the resulting
impact but the large sample size provides some reassurance
regarding robustness in these results. Furthermore, the
bootstrapped confidence intervals allowed us to capture
quantifiable uncertainty with a non-standard distribution.
Costings were based on figures provided by Quit-51 as
of the financial year 2015–2016 and the results should
be interpreted on this basis. The impact of inflation over
this period could have been taken into account, but
should not have greatly altered the findings, particularly
in regard to relative differences between the subgroups
of interest, as the inflation rate was low over the period
of this study.
Our cost per QALY findings are subject to the limita-
tions of EQUIPTMOD which have been described in
Coyle et al. [22]. We made use of the available model to
predict the value of Quit 51 against a baseline scenario
of no intervention to make meaningful predictions – this
assumption may however be an important limitation in
itself. Information on quit rates at 52 weeks was re-
corded sparingly in this dataset and therefore we used
the quit rates adopted within EQUIPTMOD. This means
that we have assumed relapse rates of approximately
70%, 81% and 88% for the NRT, varenicline and bupro-
pion treatment arms respectively subsequent to the ob-
served 12-week quit rates in Quit 51. Thus these figures
are based on a number of assumptions, but nonetheless
serve to demonstrate how parameters derived from our
calculations can be used to estimate long-term popula-
tion level cost-benefit outcomes.
Conclusions
This work has highlighted differences in CPQ between
different demographic subgroups, most notably increased
expense in relation to teenage and 20–29 year old clients,
female users and those reporting greater nicotine depend-
ence at baseline. Such information could be factored into
service provision, based on user population characteristics.
The higher costs associated with treating teenagers are
particularly important from a service planning perspective.
The CPQ for varenicline was higher than that for NRT
and bupropion, which is in contradiction to some other
studies. The data presented in this study may contribute
to future meta-analyses to resolve the relative CPQ in real
life situations.
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